DISCLAIMER While every effort is made by the publishers, editorial board, and ISN to see that no inaccurate or misleading data, opinion or statement appears in this Journal, they wish to make it clear that the data and opinions appearing in the articles and advertisements herein are the responsibility of the contributor, copyright holder, or advertiser concerned. Accordingly, the publishers and the ISN, the editorial board and their respective employers, office and agents accept no liability whatsoever for the consequences of any such inaccurate or misleading data, opinion or statement. While every effort is made to ensure that drug doses and other quantities are presented accurately, readers are advised that new methods and techniques involving drug usage, and described within this Journal, should only be followed in conjunction with the drug manufacturer s own published literature. SUPPLEMENTARY MATERIAL Supplementary Table 65. Age restriction in all RCTs for DM CKD, non- DM CKD, Transplant and CKD subgroups. Supplementary Table 66. PICO criteria for blood pressure targets in elderly studies. Supplementary Table 67. Ages and BP targets in elderly studies. Supplementary Table 68. PICO criteria for blood pressure agents in elderly studies. Supplementary material is linked to the online version of the paper at http://www.kdigo.org/clinical_practice_guidelines/bp.php Table 3 | Questions for future research Mechanisms and biology Is CKD in elderly people the same condition as CKD in young adults? How do age-related mechanisms such as fibrosis and cellular senescence interact with mechanisms underlying CKD progression? How much risk for CKD progression is determined by age versus factors such as AKI? How does fibrosis versus vessel dropout change with age? Do age- and CKD-associated changes in vascular biology differ from other parenchymal kidney disease changes associated with age? Measurement and prognosis Are there better ways to estimate GFR in older adults to identify CKD? 